Supernus Pharmaceuticals Total Long-Term Assets 2011-2024 | SUPN
Supernus Pharmaceuticals total long-term assets from 2011 to 2024. Total long-term assets can be defined as the sum of all assets classified as non-current
Supernus Pharmaceuticals Annual Total Long-Term Assets
(Millions of US $) |
| 2023 |
$785 |
| 2022 |
$968 |
| 2021 |
$1,088 |
| 2020 |
$874 |
| 2019 |
$688 |
| 2018 |
$484 |
| 2017 |
$196 |
| 2016 |
$158 |
| 2015 |
$83 |
| 2014 |
$28 |
| 2013 |
$14 |
| 2012 |
$3 |
| 2011 |
$4 |
| 2010 |
$ |
Supernus Pharmaceuticals Quarterly Total Long-Term Assets
(Millions of US $) |
| 2024-09-30 |
$703 |
| 2024-06-30 |
$725 |
| 2024-03-31 |
$760 |
| 2023-12-31 |
$785 |
| 2023-09-30 |
$836 |
| 2023-06-30 |
$870 |
| 2023-03-31 |
$908 |
| 2022-12-31 |
$968 |
| 2022-09-30 |
$1,029 |
| 2022-06-30 |
$1,070 |
| 2022-03-31 |
$1,071 |
| 2021-12-31 |
$1,088 |
| 2021-09-30 |
$887 |
| 2021-06-30 |
$934 |
| 2021-03-31 |
$921 |
| 2020-12-31 |
$874 |
| 2020-09-30 |
$958 |
| 2020-06-30 |
$934 |
| 2020-03-31 |
$633 |
| 2019-12-31 |
$688 |
| 2019-09-30 |
$680 |
| 2019-06-30 |
$673 |
| 2019-03-31 |
$605 |
| 2018-12-31 |
$484 |
| 2018-09-30 |
$532 |
| 2018-06-30 |
$568 |
| 2018-03-31 |
$242 |
| 2017-12-31 |
$196 |
| 2017-09-30 |
$194 |
| 2017-06-30 |
$181 |
| 2017-03-31 |
$172 |
| 2016-12-31 |
$158 |
| 2016-09-30 |
$147 |
| 2016-06-30 |
$104 |
| 2016-03-31 |
$101 |
| 2015-12-31 |
$83 |
| 2015-09-30 |
$64 |
| 2015-06-30 |
$48 |
| 2015-03-31 |
$38 |
| 2014-12-31 |
$28 |
| 2014-09-30 |
$23 |
| 2014-06-30 |
$22 |
| 2014-03-31 |
$18 |
| 2013-12-31 |
$14 |
| 2013-09-30 |
$21 |
| 2013-06-30 |
$21 |
| 2013-03-31 |
$3 |
| 2012-12-31 |
$3 |
| 2012-09-30 |
$4 |
| 2012-06-30 |
$2 |
| 2012-03-31 |
$5 |
| 2011-12-31 |
$4 |
| 2011-09-30 |
|
| 2011-06-30 |
|
| 2011-03-31 |
|
| 2010-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$1.978B |
$0.608B |
|
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
|
